Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River Laboratories

Argenta and BioFocus acquisition drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories
 
3Q Revenues:  $327.6 million (+12%)

3Q Earnings: $32.0 million (+4%)

YTD Revenues: $968.1 million (+10%)

YTD Earnings: $99.5 million (+19%)

Comments: Revenue growth was driven by the acquisition of Argenta and BioFocus, which was completed on April 1, 2014 and contributed 8% to 3Q revenue, as well as double-digit growth in the Manufacturing Support segment. Research Models and Services segment revenue was flat at $124.0 million in the quarter. Discovery and Safety Assessment revenue was $140.9 million, up 25% driven primarily by the acquisition of Argenta and BioFocus, which contributed 21%. Revenue for the Manufacturing segment was $62.7 million in the quarter, up 13%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters